Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia

Area of Science:

• Biochemistry
• Human Physiology
• Metabolic Disorders

Background:

• Type V hyperlipidemia is characterized by elevated triglycerides and very low-density lipoprotein (VLDL) cholesterol.
• Sodium-lithium countertransport (SLC) is a key transporter involved in cellular ion balance.
• Understanding SLC kinetics in hyperlipidemia may offer insights into metabolic regulation.

Purpose of the Study:

• To investigate sodium-lithium countertransport (SLC) kinetics in patients with type V hyperlipidemia.
• To compare SLC activity and maximal velocity between type V hyperlipidemia, type IIB hyperlipidemia, and healthy controls.
• To determine correlations between SLC parameters and clinical/biochemical markers in type V hyperlipidemia.

Main Methods:

• Measured SLC kinetics (activity and maximal velocity) in erythrocytes of 30 type V hyperlipidemia patients, 30 type IIB hyperlipidemia patients, and 30 healthy controls.
• Collected anthropometric, blood pressure, lipid biochemistry, glucose, insulin, and leptin data.
• Analyzed correlations between SLC maximal velocity and various clinical and biochemical parameters, including VLDL triglycerides and insulin resistance.

Main Results:

• Patients with type V hyperlipidemia exhibited higher obesity, elevated triglycerides, glucose, and insulin, with reduced HDL cholesterol compared to type IIB controls.
• Median SLC activity and maximal velocity were numerically higher in type V hyperlipidemia patients but not statistically significant compared to controls.
• SLC maximal velocity showed a strong positive correlation with log triglycerides (r²=0.853) and log VLDL triglycerides (r²=0.947) in type V hyperlipidemia patients.

Conclusions:

• Very low-density lipoprotein (VLDL) triglyceride levels are strongly correlated with sodium-lithium countertransport (SLC) maximal velocity and activity in type V hyperlipidemia.
• While not statistically significant in this cohort, trends suggest potentially altered SLC kinetics in type V hyperlipidemia.
• SLC transporter sodium affinity remained independent of clinical and biochemical parameters across all groups.